Oragenics submitted its Investigator's Brochure for ONP-002, preparing for a Phase II trial for mild traumatic brain injury. Oragenics, Inc., a biotechnology company based in Sarasota, Florida ...

“Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet ...

We expect AEMD to submit the Clinical Investigator Brochure this month. AEMD will then seek to obtain approval by the respective Ethics Boards of interested sites in India.

“The submission of our Investigator’s Brochure application marks a critical step forward in advancing our clinical program for ONP-002,” said Janet Huffman, Interim CEO of Oragenics.

Despite the high incidence of concussions, no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. "The submission of our Investigator's Brochure application marks a ...

SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, ...